Literature DB >> 14992686

Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.

Jack U Flanagan1, Jean-Didier Maréchal, Richard Ward, Carol A Kemp, Lesley A McLaughlin, Michael J Sutcliffe, Gordon C K Roberts, Mark J I Paine, C Roland Wolf.   

Abstract

Although the residues that determine the preference of CYP2D6 (cytochrome P450 2D6) for compounds containing a basic nitrogen are well characterized, the contribution of other active site residues to substrate binding and orientation is less well understood. Our structural model of CYP2D6 identifies the aromatic residue Phe120 as a likely major feature of the active site. To examine the role of Phe120, mutants of CYP2D6 in which this residue has been substituted by alanine, leucine, tyrosine, serine, histidine, tryptophan or methionine residues have been prepared in bacterial membranes co-expressing human cytochrome NADPH cytochrome P450 oxidoreductase. The mutants have been characterized using the prototypical bufuralol 1' hydroxylase and dextromethorphan O- and N-demethylase activities of CYP2D6. Larger effects on K(m) values are observed for dextromethorphan O-demethylation than for bufuralol 1' hydroxylation, indicating that the Phe120 side chain is more important in dextromethorphan than in bufuralol binding. A role for this side chain in determining the regiospecificity of substrate oxidation was indicated by changes in the relative rates of O- and N-demethylation of dextromethorphan and, notably, by the formation of 7-hydroxy dextromethrophan, a novel dextromethorphan metabolite, in mutants in which it had been substituted. Computational studies of dextromethorphan binding to the active site of the Phe120-->Ala mutant were carried out to throw light on the way in which the removal of this side chain leads to different modes of ligand binding.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14992686      PMCID: PMC1224184          DOI: 10.1042/BJ20040062

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  38 in total

Review 1.  Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites.

Authors:  S Ekins; M J de Groot; J P Jones
Journal:  Drug Metab Dispos       Date:  2001-07       Impact factor: 3.922

2.  Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity.

Authors:  I H Hanna; M S Kim; F P Guengerich
Journal:  Arch Biochem Biophys       Date:  2001-09-15       Impact factor: 4.013

3.  Comparative protein modelling by satisfaction of spatial restraints.

Authors:  A Sali; T L Blundell
Journal:  J Mol Biol       Date:  1993-12-05       Impact factor: 5.469

4.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation.

Authors:  G Jones; P Willett; R C Glen
Journal:  J Mol Biol       Date:  1995-01-06       Impact factor: 5.469

5.  Progesterone oxidation by cytochrome P450 2D isoforms in the brain.

Authors:  T Hiroi; W Kishimoto; T Chow; S Imaoka; T Igarashi; Y Funae
Journal:  Endocrinology       Date:  2001-09       Impact factor: 4.736

6.  Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.

Authors:  G P Hayhurst; J Harlow; J Chowdry; E Gross; E Hilton; M S Lennard; G T Tucker; S W Ellis
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

7.  Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6.

Authors:  A Yu; H Dong; D Lang; R L Haining
Journal:  Drug Metab Dispos       Date:  2001-11       Impact factor: 3.922

8.  Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding.

Authors:  F Peter Guengerich; Grover P Miller; Imad H Hanna; Martha V Martin; Serge Léger; Cameron Black; Nathalie Chauret; José M Silva; Laird A Trimble; James A Yergey; Deborah A Nicoll-Griffith
Journal:  Biochemistry       Date:  2002-09-10       Impact factor: 3.162

Review 9.  Recombinant yeast in drug metabolism.

Authors:  J P Renaud; M A Peyronneau; P Urban; G Truan; C Cullin; D Pompon; P Beaune; D Mansuy
Journal:  Toxicology       Date:  1993-10-05       Impact factor: 4.221

10.  Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,alpha-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6.

Authors:  J M Grace; M T Kinter; T L Macdonald
Journal:  Chem Res Toxicol       Date:  1994 May-Jun       Impact factor: 3.739

View more
  14 in total

1.  Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism.

Authors:  Rayomand J Unwalla; Jason B Cross; Sumeet Salaniwal; Adam D Shilling; Louis Leung; John Kao; Christine Humblet
Journal:  J Comput Aided Mol Des       Date:  2010-04-02       Impact factor: 3.686

2.  Understanding the determinants of selectivity in drug metabolism through modeling of dextromethorphan oxidation by cytochrome P450.

Authors:  Julianna Oláh; Adrian J Mulholland; Jeremy N Harvey
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-28       Impact factor: 11.205

3.  CYP2D6 Allelic Variants *34, *17-2, *17-3, and *53 and a Thr309Ala Mutant Display Altered Kinetics and NADPH Coupling in Metabolism of Bufuralol and Dextromethorphan and Altered Susceptibility to Inactivation by SCH 66712.

Authors:  Sarah M Glass; Cydney M Martell; Alexandria K Oswalt; Victoria Osorio-Vasquez; Christi Cho; Michael J Hicks; Jacqueline M Mills; Rina Fujiwara; Michael J Glista; Sharat S Kamath; Laura Lowe Furge
Journal:  Drug Metab Dispos       Date:  2018-05-21       Impact factor: 3.922

4.  Free energies of binding of R- and S-propranolol to wild-type and F483A mutant cytochrome P450 2D6 from molecular dynamics simulations.

Authors:  Chris de Graaf; Chris Oostenbrink; Peter H J Keizers; Barbara M A van Vugt-Lussenburg; Jan N M Commandeur; Nico P E Vermeulen
Journal:  Eur Biophys J       Date:  2007-02-27       Impact factor: 1.733

Review 5.  Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions.

Authors:  J-D Maréchal; C A Kemp; G C K Roberts; M J I Paine; C R Wolf; M J Sutcliffe
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

Review 6.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Tryptophan-75 Is a Low-Energy Channel-Gating Residue that Facilitates Substrate Egress/Access in Cytochrome P450 2D6.

Authors:  Kevin D McCarty; Samuel A Ratliff; Kyle A Furge; Laura Lowe Furge
Journal:  Drug Metab Dispos       Date:  2020-12-29       Impact factor: 3.922

8.  Biochemical comparison of Anopheles gambiae and human NADPH P450 reductases reveals different 2'-5'-ADP and FMN binding traits.

Authors:  Lu-Yun Lian; Philip Widdowson; Lesley A McLaughlin; Mark J I Paine
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

9.  Functional characterization of a first avian cytochrome P450 of the CYP2D subfamily (CYP2D49).

Authors:  Hua Cai; Jun Jiang; Qi Yang; Qingmei Chen; Yiqun Deng
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

10.  Efficicent (R)-phenylethanol production with enantioselectivity-alerted (S)-carbonyl reductase II and NADPH regeneration.

Authors:  Rongzhen Zhang; Botao Zhang; Yan Xu; Yaohui Li; Ming Li; Hongbo Liang; Rong Xiao
Journal:  PLoS One       Date:  2013-12-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.